IDEAYA Biosciences, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Phone 650-443-6209
Fiscal Year End 1231
EIN 474268251
Financial Overview
FY2025
-$112.96M
Net Income
$1.12B
Total Assets
$-1.28
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 2, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 10-K Annual financial report | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
Annual Reports
10-K February 17, 2026
- Significant financial growth in 2025, with revenue surging to $215.3 million and net loss substantially reduced to $113.7 million.
- Robust cash position of approximately $1.05 billion, providing a liquidity runway for at least twelve months.
Insider Trading
BUY 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.